C(=o)o Attached Directly Through The Carbon To A Benzene Ring Patents (Class 514/544)
-
Publication number: 20110301236Abstract: A novel compound isolated from the plant Garcinia paucinervis. The compound's structure is as follows: The compound possesses a potent ability to activate caspase-3 in HeLa-C3 cells within 72 h at a low concentration of 25 ?M. The IC50 on HeLa cells for this compound was measured to be below 10 ?M, indicating a strong HeLa cell growth inhibitory effect.Type: ApplicationFiled: June 4, 2010Publication date: December 8, 2011Inventors: XUE-MEI GAO, Ting Yu, Kathy Qian Luo, Hong Xi Xu
-
Patent number: 8071644Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.Type: GrantFiled: January 13, 2009Date of Patent: December 6, 2011Assignee: Galderma Research & DevelopmentInventors: Marie-line Abou-Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
-
Publication number: 20110268679Abstract: Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives.Type: ApplicationFiled: July 11, 2011Publication date: November 3, 2011Inventor: David SHERRIS
-
Patent number: 8044098Abstract: This invention provides hydroxybenzoic acids, their esters and analogues thereof that are useful for the prevention and/or treatment of virus infection such as HBV, papillomavirus and/or herpes virus infection.Type: GrantFiled: February 1, 2008Date of Patent: October 25, 2011Assignee: Shenghua Guangzhou Pharmaceutical Science & Technology Co., Ltd.Inventor: Weihua Qin
-
Publication number: 20110218155Abstract: The invention provides a method for identifying a compound which modulates the activity of a BCL-2 family polypeptide, the method comprising: a) contacting said BCL-2 family polypeptide with a compound under conditions suitable for modulation of the activity of said BCL-2 family polypeptide; and b) detecting modulation of the activity of said BCL-2 family polypeptide by the compound, wherein the compound interacts with a binding site comprising one or more of an ?1 helix, ?2 helix, a loop between ?1-?2, ?.6 helix, and select residues of ?4, ?.5, and ?.8 helices in said BCL-2 family polypeptide; wherein the interaction of the compound with the binding site occurs at a horizontal hydrophobic groove with or without a perimeter of charged and hydrophilic residues, a superior juxta-loop, an inferior juxta-loop, or combination thereof.Type: ApplicationFiled: October 9, 2009Publication date: September 8, 2011Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Evripidis Gavathiotis
-
Publication number: 20110207817Abstract: This invention relates to alkyl parabens, their use as anti-inflammatory agents and compositions containing them.Type: ApplicationFiled: November 10, 2009Publication date: August 25, 2011Inventors: Sean M. Wetterer, Jingjun Yang
-
Patent number: 7981460Abstract: The present invention relates to a pharmaceutical composition, a food composition or a cosmetic composition, containing one or more kinds of a compound represented by the following formula (I?) wherein R1 is a hydrogen atom, a hydroxyl group, a methoxy group or an ethoxy group, R2 is a hydroxyl group, a methoxy group or an acetoxy group, or R1 and R2 in combination optionally form a methylenedioxy group, R is represented by the following formula wherein Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=2 to 8, and R3 and R4 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that, (1) when R1 is a methoxy group, then R2 is not a hydroxyl group; and (2) when R1 is a hydroxyl group, then R2 is not a hydroxyl group and an acetoxy group.Type: GrantFiled: December 29, 2008Date of Patent: July 19, 2011Assignee: Ajinomoto Co., Inc.Inventors: Yusuke Amino, Yoshinobu Takino
-
Publication number: 20110166157Abstract: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl)propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl)propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methyl or ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.Type: ApplicationFiled: March 11, 2011Publication date: July 7, 2011Applicant: ALBIREO ABInventors: Anders Broo, Johan Gottfries, Michael Kossenjans, Li Lanna, Eva-Lotte Lindstedt-Alstermark, Kristina A. Nilsson, Bengt Ohlsson, Maria Thorstensson, Maria Boije, Per Olof Sjögren
-
Patent number: 7968124Abstract: Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and attenuate the effect of drugs and toxins, and may be used as a rescue or reversal agent, or as a prophylaxis. The invention is especially applicable in reversing adverse effects of local anesthetics inadvertently delivered systemically, and attenuating the therapeutic effects of general anesthetics in the course of treatment.Type: GrantFiled: December 6, 2007Date of Patent: June 28, 2011Assignee: Lyotropic Therapeutics, Inc.Inventors: David M. Anderson, Vincent M. Conklin, Benjamin G. Cameransi
-
Publication number: 20110136901Abstract: The present invention discloses 4-nerolidylcatechol and its derivatives isolated from South American/Amazon plants (Pothomorphe species) and their potential use as therapeutical agent for treatment of malarial symptoms, including malarial patients resistant to traditional drugs. The present invention also discloses a method for producing 4-nerolidylcatechol and their derivatives.Type: ApplicationFiled: December 28, 2007Publication date: June 9, 2011Inventors: Ana Cristina Da Silva Pinto, Màrcia Rùbia Silva Melo, Valter Ferreira De Andrade Neto, Francisco Célio Maia Chaves, Pedro Paulo Ribeiro Vieira, Adrian Martin Pohlit
-
Publication number: 20110110914Abstract: Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.Type: ApplicationFiled: May 11, 2010Publication date: May 12, 2011Inventors: Niven Rajin Narain, John Patrick McCook, Rangaprasad Sarangarajan
-
Publication number: 20110082176Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.Type: ApplicationFiled: October 15, 2010Publication date: April 7, 2011Inventors: Norman C.W. Wong, Joseph E.L. Tucker, Henrik C. Hansen, Fabrizio S. Chiacchia, David McCaffrey
-
Patent number: 7910090Abstract: The present invention provides a base composition that allows for the formulation of non-irritating cosmetic and/or dermatological compositions. The base composition includes one or more of electrolyte, buffer, mild preservative, lubricant, or any combinations thereof. It is preferred that one or more of the above components are eye-safe and/or eye-compatible. The present invention also provides photoprotective cosmetic and/or dermatological compositions that include the base composition and one or more sunscreen active components and are non-irritating to mammalian eyes.Type: GrantFiled: January 18, 2006Date of Patent: March 22, 2011Assignee: Playtex Products, Inc.Inventors: Olga V. Dueva-Koganov, James P. SaNogueira
-
Publication number: 20110065657Abstract: Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by ?-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.Type: ApplicationFiled: September 21, 2010Publication date: March 17, 2011Inventors: Gerardo M Castillo, Paula Choi, Alan D Snow
-
Publication number: 20110046220Abstract: The invention relates to a Microbulbifer bacterial strain isolated from a marine sponge, to its use in a process for manufacturing paraben compounds. The invention also relates to paraben compounds obtained from that Microbulbifer strain and to their uses. The Microbulbifer strain of the invention is Microbulbifer strain named L4-N2 deposited at the CNCM under the registration number 1-3714. The process of manufacturing paraben compounds of the invention makes use of this Microbulbifer strain. The invention finds application in the manufacture of paraben compounds, for use in particular in cosmetic, pharmaceutical, antifouling, detergent, sanitizing and disinfectant compositions.Type: ApplicationFiled: April 7, 2008Publication date: February 24, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MUSEUM NATIONAL D'HISTOIRE NATURELLE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)Inventors: Marie-Lise Bourguet-Kondracki, Isabelle Domart-Coulon, Elodie Quevrain
-
Publication number: 20110039701Abstract: The invention relates to novel compounds of the formula (I) in which X, Y, Z, A, B and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the phenyl-substituted bicyclooctane-1,3-dione derivates 33 and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or acaricides and/or for preventing unwanted plant growth.Type: ApplicationFiled: March 30, 2010Publication date: February 17, 2011Applicant: Bayer CropScience AGInventors: Alfred ANGERMANN, Guido Bojack, Reiner Fischer, Stefan Lehr, Jan Dittgen, Dieter Feucht, Isolde Häuser-Hahn, Christopher Hugh Rosinger, Arnd Voerste
-
Publication number: 20110028545Abstract: The present invention relates to a process for producing concentrates of antimicrobial active ingredients, the concentrates themselves and their use for producing solid, liquid or pasty body cleaning compositions, such as in particular soaps.Type: ApplicationFiled: January 12, 2009Publication date: February 3, 2011Applicant: LANXESS DEUTSCHLAND GMBHInventors: Gerd-Friedrich Renner, Otto Exner, Rolf Matysiak, Josef Wellmann, Udo Hennen
-
Publication number: 20110021623Abstract: Inhibiting the enzymic action of tyrosinase in the melanocyte prior to, during, or after ultraviolet (UV) radiation exposure, including over-exposure causing erythema, or sunburn, prevents the production of melanin and thereby melanoma. Melanoma can be prevented by using a tyrosinase inhibitor agent that inhibits the enzymic action of tyrosinase to prevent damage and/or death of melanocytes. The inhibitor agent can be applied to the skin or ingested.Type: ApplicationFiled: September 30, 2010Publication date: January 27, 2011Applicant: Regents of the University of New MexicoInventors: Graham TIMMINS, Leslie Paige Lund
-
Publication number: 20100330011Abstract: Silicone organic gels and gel paste compositions are disclosed containing a silicone organic elastomer in a carrier fluid. The silicone organic elastomer is a reaction product of a linear or branched organohydrogensiloxane, an ?, ?-unsaturated polyoxyalkylene, and a hydrosilylation catalyst. The silicone organic elastomer is particularly useful to ge! organic earner fluids, The gels and gels pastes also provide enhanced compatibility with many personal and health care actives.Type: ApplicationFiled: June 24, 2008Publication date: December 30, 2010Inventors: John Joseph Kennan, Kathryn Elizabeth Messner
-
Publication number: 20100330001Abstract: The present invention relates to oral antibacterial compositions comprising trihydroxybenzoate derivatives, e.g., useful for the treatment of gum diseases (e.g., gingivitis or periodontitis) and to methods of using such compositions.Type: ApplicationFiled: April 16, 2010Publication date: December 30, 2010Inventors: Toshihisa Kawai, Phllip P. Stashonko, Yoshiaka Hosokawa, Kazuhisa Ohara
-
Publication number: 20100311738Abstract: The present invention relates to a pharmaceutical composition in the form of a storage-stable solution for the parenteral administration of ultrashort-effective ?-adrenoreceptor antagonists, comprising a) an ultrashort-effective ?-adrenoreceptor antagonist and/or a pharmaceutically acceptable salt thereof, b) water, and c) a cyclodextrin and/or a functional cyclodextrin derivative. The composition according to the invention has high stability, even without the presence of additional adjuvants.Type: ApplicationFiled: December 22, 2008Publication date: December 9, 2010Applicant: AOP ORPHAN PHARMACEUTICALS AGInventor: Rudolf Stefan Widmann
-
Publication number: 20100310494Abstract: A Styrax Benzoin Rejuvenating Cosmetic Preparation for immediate noticeable beneficial results on whole body, face and skin, embodying chemical constituents comprising, Benzoic acid, Cinnamic Acid, Benzoic Aldehyde, Vanillin Aldehyde, Benzyl Benzoate, and optionally, as well as additionally, a face cream base which includes Glycerine, Triglyceride, Polyacrylate, Phenoxyethamol, Methylparaben, Ethylparaben & Water.Type: ApplicationFiled: November 10, 2008Publication date: December 9, 2010Inventor: Anushya Sundaresan
-
Publication number: 20100298200Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.Type: ApplicationFiled: May 22, 2009Publication date: November 25, 2010Inventors: Dakai Liu, Xiaofeng Li, Richard Jin, Yuaxin Liang, Wei Cheng, Riddhi Bhattacharyya, Guangrong Zhang
-
Publication number: 20100291010Abstract: A novel ester of an optionally substituted aromatic acid (for example benzoic acid) and a branched C13 primary alcohol is suitable for use in providing improved cosmetic and personal care compositions including sunscreen, antiperspirant and deodorant compositions.Type: ApplicationFiled: December 23, 2008Publication date: November 18, 2010Applicant: INNOSPEC LIMITEDInventors: Samad Syed, Phillip Cotrell
-
Publication number: 20100279971Abstract: This invention relates to compounds of the formula X) or XI) (X) (XI) wherein: each —R1, —R2 and —R3 is independently -Q1, —OH or —H, where at least one of —R1, —R2 and —R3 is not —H or —OH; each —R4 and —R5 is independently -Q2 or —H; each -Q1 is independently selected from: —F, —Cl, —RA, —ORA, —SH, —SRA, where each —RA is independently selected from methyl and ethyl, which may substituted by one or more fluoro or chloro groups; and each -Q2 is selected from: —F, —Cl, —RB, —ORB, —SH, —SRB, where each —RB is independently selected from methyl and ethyl, which may substituted by one or more fluoro or chloro groups; which are useful in the treatment of melanoma.Type: ApplicationFiled: December 18, 2008Publication date: November 4, 2010Inventors: Jose Neptuno Rodriguez-Lopez, Luis Sanchez Del Campo Ferrer, Juan Cabezas-Herrera, Alberto Tarraga Tomas, Magali Maria Saez Ayala
-
Publication number: 20100267827Abstract: The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: August 1, 2007Publication date: October 21, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Laura Rubio Arrieta, Esther Garcia Palomero, Pablo Garcia Fernandez, Celia De Austria De Luque, Elena Delgado Hernandez, Paola Usan Egea, Rita Valenzuela Liminana, Jorge Sanchez-Quesada
-
Publication number: 20100267778Abstract: The present invention relates to a compound represented by formula (I): wherein ring A, ring B and ring D each independently represents a cyclic group which may have a substituent(s); W is a spacer having 1 to 8 atom(s) in its main chain; X is a spacer having 1 to 2 atom(s) in its main chain; Y is a binding bond or a spacer having 1 to 8 atom(s) in its main chain; and Z is an acidic group, or a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I) has a PPAR ? agonistic action and is useful as a preventive and/or treating agent for diseases where sugar and lipid metabolisms are abnormal (diabetes, hyperlipemia, arteriosclerosis, cardiovascular diseases, obesity and metabolic syndrome or the like), hypertension, circulatory diseases and skin inflammation diseases.Type: ApplicationFiled: August 3, 2004Publication date: October 21, 2010Inventors: Shinya Kusuda, Yoshisuke Nakayama, Masaki Ima, Hisao Tajima, Sachiko Kato
-
Publication number: 20100267677Abstract: This invention relates to the control of plant pests, such as aphid and whitefly by treating plants with a compound which inhibits the plant pest's ability to overcome plant defence responses, such as piperonyl butoxide or propyl gallate, in combination with a compound which activates plant defence responses, such as cis-Jasmone or beta-amino butyric acid.Type: ApplicationFiled: May 5, 2010Publication date: October 21, 2010Applicant: Plant Bioscience LimitedInventors: Graham Moores, Georgina Bingham
-
Publication number: 20100255107Abstract: A therapeutic, cosmetic or cosmeceutic composition for topical application, capable of stabilizing an active ingredient and delivering the active ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 micron. The core of each microcapsule includes at least one active ingredient, and is encapsulated within a microcapsular shell. The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and is designed to release the active ingredient from the microcapsules following application. The composition is useful in encapsulating active ingredients, such as benzoyl peroxide, that are unstable in other formulation, or are irritating to the skin.Type: ApplicationFiled: June 18, 2010Publication date: October 7, 2010Applicant: SOL-GEL TECHNOLOGIES LTD.Inventors: Noa Lapidot, Shlomo Magdassi, David Avnir, Claudio Rottman, Orit Gans, Alon Seri-Levy
-
Publication number: 20100256576Abstract: Disinfectant compositions including EDTA salt(s), Parabens and Methylene Blue. The disinfectant compositions have demonstrated activity as enhanced, fast acting catheter lock/flush solutions. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. In addition, the composition has anticoagulant activity and can be utilized to maintain the patency of catheters.Type: ApplicationFiled: April 7, 2010Publication date: October 7, 2010Applicant: TYCO HEALTHCARE GROUP LPInventors: Dinesh Aggarwal, Chirag B. Shah
-
Publication number: 20100249075Abstract: The present invention relates to novel tetralin ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.Type: ApplicationFiled: February 10, 2006Publication date: September 30, 2010Applicant: ELI LILLY AND COMPANYInventors: Venkatesh Krishnan, Julian Stanley Kroin, Bryan Hurst Norman, Elizabeth Marie Thomas
-
Publication number: 20100240657Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition with the above-mentioned properties.Type: ApplicationFiled: July 1, 2008Publication date: September 23, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Martin Steegmaier, Steffen Steurer, Irene Waizenegger
-
Publication number: 20100240750Abstract: This invention relates to compositions, methods, devices and kits relating to the infusion of a catheter lock solution into an indwelling catheter. Inventive compositions, methods, devices and kits aid in diminishing the effects of microbial infection in catheters and occlusion of the catheters. A lock solution provided by the invention includes citrate and a paraben. The solution preferably has a density suitable for retention of the solution in a catheter during the lock period. Another lock solution provided by the invention includes citrate, a paraben and a photo-oxidant, such as, for example, methylene blue.Type: ApplicationFiled: June 2, 2010Publication date: September 23, 2010Applicant: Ash Access Technology Inc.Inventors: Stephen R. Ash, Janusz Steczko, Gary L. Swanson
-
Publication number: 20100233022Abstract: The present invention includes a composition for enhancing the antimicrobial efficacy of photodynamic disinfection against Gram-negative organism that is receptive to paraben potentiation using a composition comprising a photosensitizer and at least one paraben. The present invention also includes a method for photodynamic disinfection comprising applying the composition to a desired treatment area and applying light to the desired treatment area at a wavelength absorbed by the photosensitizer so as to inhibit Gram-negative organism located within the treatment area wherein the Gram-negative organism is receptive to paraben potentiation.Type: ApplicationFiled: October 22, 2009Publication date: September 16, 2010Inventors: Cale Street, Lisa Pedigo, Nicholas Loebel
-
Publication number: 20100233185Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.Type: ApplicationFiled: May 24, 2010Publication date: September 16, 2010Inventors: Patricia Denny, Paul C. Denny, Mahvash Navazesh
-
Publication number: 20100226872Abstract: The present invention is a directed to a composition and method of solubilizing and stabilizing a liquid preservative composition containing an alkyl paraben ingredient which comprises including polyvinyl pyrrolidone (PVP) in said composition. The compositions are particularly useful in personal care products.Type: ApplicationFiled: August 8, 2007Publication date: September 9, 2010Inventors: John J. Merianos, Susan M. Lindstrom, Paul Garelick
-
Publication number: 20100226983Abstract: The present invention relates to methods for treating and preventing acne or P. acnes infection in a subject comprising topically administering to the subject in need thereof an anti-acne nanoemulsion composition.Type: ApplicationFiled: January 28, 2010Publication date: September 9, 2010Inventors: Joyce A. Sutcliffe, Susan M. Ciotti, James R. Baker, JR.
-
Patent number: 7781485Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoic acid derivative represented by General Formula (I): [wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aroyl, or the like; R2 represents —NR14R15 (wherein R14 and R15 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R3 and R5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like; and R4 and R6 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl or the like] or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoic acid derivative or said prodrug.Type: GrantFiled: November 9, 2005Date of Patent: August 24, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Yushi Kitamura, Yutaka Kanda, Takayuki Nakashima
-
Publication number: 20100210524Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are as defined in the specification. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.Type: ApplicationFiled: July 21, 2008Publication date: August 19, 2010Inventors: Theresa Apelqvist, Joakim Löfstedt, Thomas Norin, Mattias Wennerstål, Xiongyu Wu, Lars Hagberg
-
Publication number: 20100197661Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.Type: ApplicationFiled: March 23, 2010Publication date: August 5, 2010Inventors: Gideon Dreyfuss, Jin Wang
-
Publication number: 20100190856Abstract: The present invention relates to new polyhydroxylated compounds and, in particular, to its activity as fatty acid synthase (FASN) inhibitors and to their use for the treatment of pathological states for which an inhibitor of this enzyme is indicated. The invention further relate to pharmaceutical compositions containing them and to a process for the preparation of such compounds.Type: ApplicationFiled: June 25, 2008Publication date: July 29, 2010Applicant: UNIVERSIDAD COMPLUTENSE DE MADRIDInventors: Ramón Colomer Bosch, Teresa Puig Miquel, Joan Brunet Vidal, María Luz López Rrodríguez, Bellinda Benhamú Salama, Silvia Ortega Gutiérrez, Carlos Turrada García
-
Publication number: 20100189818Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: January 19, 2010Publication date: July 29, 2010Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: GUOCHUAN EMIL TSAI
-
Publication number: 20100168228Abstract: Novel compounds, their methods of preparation and use in therapies related to cancer and inflammation are provided. Compounds comprise esters of cinnamic acid, vanillic acid and 4-hydroxy cinnamic acid and derivatives and salts thereof. Compounds with novel benzofuran lignan structure as a potent antimitotic agent and inducer of apoptosis are provided. Formulations and methods for treatment of diseases mediated by NF-kappaB are also provided.Type: ApplicationFiled: October 12, 2007Publication date: July 1, 2010Applicant: RELIANCE LIFE SCIENCES PVT. LTD.Inventors: Julie Saha Bose, Vijay Gangan
-
Publication number: 20100144873Abstract: Disclosed are methods of treating myocarditis by—administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 17, 2009Publication date: June 10, 2010Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoel Kloog, Jakob George, Gad Keren, Rakefet Pando
-
Publication number: 20100120910Abstract: The invention relates to the use of esters of 2-propylheptanol with benzoic acid and/or benzoic acid derivatives in cosmetic and/or pharmaceutical preparations. The compounds are distinguished by their particularly light sensory impression.Type: ApplicationFiled: April 17, 2008Publication date: May 13, 2010Applicant: COGNIS IP MANAGEMENT GMBHInventor: Markus Dierker
-
Publication number: 20100087524Abstract: One aspect of the invention relates to a product selected from the group consisting of foodstuffs, beverages, oral care products, tobacco products and flavourings, said product containing at least 0.01 mg/kg of one or more flavour improving substances selected from the group of substituted phenol esters represented by the following the formula, salts of these compounds and combinations thereof: Formula (I). The invention also relates to novel substituted phenol esters represented by the above formula.Type: ApplicationFiled: November 20, 2007Publication date: April 8, 2010Inventors: Stephan Haiber, Thorsten Koenig, Eric Kohlen, Adri De Klerk, Chris Winkel
-
Publication number: 20100056507Abstract: The present invention relates to new phenylic derivatives exhibiting a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. These derivatives are of particular interest in a method for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said new phenylic derivatives and to methods for the preparation and use thereof.Type: ApplicationFiled: October 26, 2007Publication date: March 4, 2010Applicant: IPSEN PHARMA S.A.S.Inventors: Lydie Poitout, Jeremiah Harnett, Dennis Bigg, Carole Sackur, Eric Ferrandis
-
Publication number: 20100040682Abstract: The present invention relates to a novel galenic formulation of fenofibrate for oral administration and to the process for its preparation. According to the invention, the formulation is a tablet obtained by compressing a mixture comprising: a) granules containing: 1 to 5% of a surfactant; micronized fenofibrate; and at least one solid excipient selected from starch, cellulose and derivatives thereof, with the exception of C12 disaccharides, said granules being obtained by granulating the mixture with the aid of an aqueous solution of polyvinylpyrrolidone; b) crosslinked polyvinylpyrrolidone; and c) optionally flow aids or lubricants, the amount of fenofibrate being greater than 50% by weight, expressed relative to the weight of the tablet.Type: ApplicationFiled: October 21, 2009Publication date: February 18, 2010Applicant: LABORATOIRES FOURNIER S.A.Inventors: Pascale Blouquin, Philippe Reginault
-
Patent number: 7652042Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: June 2, 2008Date of Patent: January 26, 2010Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Publication number: 20100010086Abstract: The invention relates to compositions that provide antimicrobial therapy for indwelling catheters and as topical disinfectants, and methods, devices and kits relating thereto. In one aspect, the invention relates to the infusion of a catheter lock solution into an indwelling catheter. Use of inventive compositions as catheter lock solutions advantageously aid in diminishing the effects of microbial infection in catheters and occlusion of the catheters. In other aspects, antimicrobial compositions are used to topically sanitize wounds, skin areas and/or other surfaces. An antimicrobial composition provided by the invention includes EDTA, a paraben, and optionally one or both of citrate and a photo-oxidant.Type: ApplicationFiled: August 3, 2007Publication date: January 14, 2010Inventors: Stephen R. Ash, Janusz Steczko